Semaglutide, FITC labeled

MedChem Express

Semaglutide, FITC labeled

5

Research Use Only

99.83

C208H302N46O64S

4502.96

Semaglutide, FITC labeled is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide, FITC labeled promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide, FITC labeled also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide, FITC labeled has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinsons disease models, reducing alpha-synuclein aggregation) and improving hepatic steatosis. Semaglutide, FITC labeled can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinsons disease, metabolic associated fatty liver disease (MASLD), and cancer[1][2][3][4][5].

O=C([C@H](CC1=CN=CN1)NC(NC2=CC3=C(C4(C5=C(OC6=CC(O)=CC=C64)C=C(C=C5)O)OC3=O)C=C2)=S)NC(C)(C(N[C@H](C(NCC(N[C@H](C(N[C@@H](CC7=CC=CC=C7)C(N[C@H](C(N[C@H](C(N[C@@H](CC(O)=O)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC8=CC=C(C=C8)O)C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@@H](C)C(N[C@@H](C)C(N[C@H](C(N[C@H](C(N[C@@H](CC9=CC=CC=C9)C(N[C@@H]([C@H](CC)C)C(N[C@@H](C)C(N[C@@H](CC%10=CNC%11=C%10C=CC=C%11)C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(NCC(O)=O)=O)CCCNC(N)=N)=O)=O)CCCNC(N)=N)=O)C(C)C)=O)CC(C)C)=O)=O)=O)=O)=O)CCC(O)=O)=O)CCCCNC(COCCOCCNC(COCCOCCNC(CCC(NC(CCCCCCCCCCCCCCCCC(O)=O)=O)C(O)=O)=O)=O)=O)=O)=O)=O)CCC(N)=O)=O)=O)CCC(O)=O)=O)CC(C)C)=O)=O)CO)=O)CO)=O)C(C)C)=O)=O)CO)=O)[C@@H](C)O)=O)=O)[C@@H](C)O)=O)=O)CCC(O)=O)=O)C

-20°C,-80°C

12162000